$27.5m settles Oxford, Qiagen patent suit

Oxford Immunotec Ltd. and Qiagen N.V. said they reached a settlement in the lawsuit in the US District Court for the District of Massachusetts in Boston alleging patent infringement in relation to Qiagen’s QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus products.

“Under terms of the agreement, all pending claims between Oxford and Qiagen and the co-defendants have been resolved,” said Oxford Immunotec.

“As part of the settlement, Oxford has granted Qiagen a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million.

“The settlement includes general releases of all parties with no admissions of wrongdoing.”